Traws Pharma shares surge 46.33% intraday after reporting Q3 cost cuts, IP acquisitions, and antiviral trial advancements.

Traws Pharma surged 46.33% intraday after reporting Q3 2025 financial results showcasing significant cost reductions, IP asset acquisitions, and progress in Phase 2 trials for antiviral therapies targeting COVID-19 and bird flu. The company highlighted a strategic pivot toward high-potential antiviral programs and partnerships, alongside a narrowed net loss, signaling improved financial efficiency. Advancements in ratutrelvir and tivoxavir marboxil development, which address multi-billion-dollar market opportunities, likely drove investor optimism despite bearish technical indicators and a "Underperform" AI rating. The news reinforced confidence in the firm’s pipeline and operational restructuring, aligning with the intraday rally.